First Quadrant’s Bristol-Myers Squibb BMY Stock Holding History

First Quadrant’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$43K	Sell	584 -24,749	-98%	-$1.66M	0.24%	27
2021 Q4	$1.58M	Hold	25,333	–	–	0.17%	119
2021 Q3	$1.5M	Hold	25,333	–	–	0.17%	116
2021 Q2	$1.69M	Sell	25,333 -9,793	-28%	-$639K	0.19%	111
2021 Q1	$2.22M	Hold	35,126	–	–	0.24%	91
2020 Q4	$2.18M	Buy	35,126 +10,484	+43%	+$645K	0.22%	84
2020 Q3	$1.49M	Sell	24,642 -3,328	-12%	-$200K	0.19%	108
2020 Q2	$1.65M	Buy	27,970 +928	+3%	+$55.5K	0.22%	109
2020 Q1	$1.51M	Sell	27,042 -23,883	-47%	-$1.46M	0.22%	117
2019 Q4	$3.27M	Buy	50,925 +45,825	+899%	+$2.62M	0.27%	84
2019 Q3	$259K	Hold	5,100	–	–	0.02%	383
2019 Q2	$231K	Hold	5,100	–	–	0.02%	501
2019 Q1	$243K	Sell	5,100 -2,572	-34%	-$128K	0.02%	465
2018 Q4	$399K	Buy	7,672 +891	+13%	+$47.9K	0.03%	399
2018 Q3	$421K	Sell	6,781 -11,882	-64%	-$705K	0.01%	519
2018 Q2	$1.03M	Hold	18,663	–	–	0.02%	403
2018 Q1	$1.18M	Hold	18,663	–	–	0.02%	386
2017 Q4	$1.14M	Sell	18,663 -388,860	-95%	-$24.3M	0.02%	413
2017 Q3	$26M	Buy	407,523 +385,136	+1,720%	+$22.5M	0.5%	46
2017 Q2	$1.25M	Buy	22,387 +17,287	+339%	+$941K	0.02%	401
2017 Q1	$277K	Hold	5,100	–	–	0.01%	607
2016 Q4	$298K	Hold	5,100	–	–	0.01%	602
2016 Q3	$275K	Sell	5,100 -24,100	-83%	-$1.55M	0.01%	607
2016 Q2	$2.15M	Sell	29,200 -26,300	-47%	-$1.86M	0.05%	289
2016 Q1	$3.54M	Buy	55,500 +23,000	+71%	+$1.45M	0.08%	240
2015 Q4	$2.24M	Buy	32,500 +27,400	+537%	+$1.81M	0.05%	300
2015 Q3	$302K	Hold	5,100	–	–	0.01%	510
2015 Q2	$339K	Sell	5,100 -300	-6%	-$19.8K	0.01%	516
2015 Q1	$348K	Sell	5,400 -2,800	-34%	-$175K	0.01%	488
2014 Q4	$484K	Sell	8,200 -86,800	-91%	-$4.9M	0.01%	447
2014 Q3	$4.86M	Buy	+95,000	New	+$4.75M	0.11%	187

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

First Quadrant's BMY Position: Q1 2022 in Review

First Quadrant reduced its Bristol-Myers Squibb (BMY) stake by 98% in Q1 2022, selling an estimated $1.66M and leaving 584 shares worth $43K. The position accounts for 0.24% of the portfolio, ranked #27.

First Quadrant first reported a position in BMY in Q3 2014 and has held it in 31 quarters since. The position peaked at $26M in Q3 2017. 2,516 funds tracked by Wall St. Rank hold BMY as of Q1 2022.

First Quadrant held 584 shares of Bristol-Myers Squibb worth $43K as of Q1 2022.
First Quadrant sold 24,749 Bristol-Myers Squibb shares in Q1 2022, an estimated $1.66M.
Bristol-Myers Squibb made up 0.24% of First Quadrant's portfolio in Q1 2022, its #27 holding.
First Quadrant first reported a position in Bristol-Myers Squibb in Q3 2014 and has held it in 31 quarters since.
First Quadrant's Bristol-Myers Squibb position peaked at $26M in Q3 2017.
2,516 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.